Clinical Trials Logo

Recurrent Small Cell Lung Cancer clinical trials

View clinical trials related to Recurrent Small Cell Lung Cancer.

Filter by:

NCT ID: NCT05162196 Not yet recruiting - Clinical trials for Recurrent Small Cell Lung Cancer

The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

Start date: June 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, multicenter, open-label study to observe the efficacy and safety of combination with radiotherapy, niraparib and toripalimab in patients With recurrent small cell lung cancer(SCLC).

NCT ID: NCT04610658 Terminated - Clinical trials for Small-cell Lung Cancer

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Start date: November 23, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy

NCT ID: NCT03732846 Recruiting - Clinical trials for Recurrent Small Cell Lung Cancer

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer

NCT ID: NCT01999881 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients

Start date: December 2013
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies exercise intervention in improving quality of life and exercise capacity and reducing inflammation and oxidative stress in patients with lung cancer and their support persons. Exercise therapy may help improve quality of life, may increase exercise capacity, and may reduce inflammation and oxidative stress in patients with lung cancer and their supporters.

NCT ID: NCT01935336 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Start date: September 24, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01931787 Completed - Clinical trials for Recurrent Small Cell Lung Cancer

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Start date: October 2013
Phase: Phase 1
Study type: Interventional

This pilot clinical trial studies CPI-613 (6,8-bis[benzylthio]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.

NCT ID: NCT01901653 Completed - Clinical trials for Recurrent Small Cell Lung Cancer

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of rovalpituzumab tesirine (SC16LD6.5) at different dose levels in patients with small cell lung cancer whose cancer has progressed or recurred following standard chemotherapy. Once a safe and tolerable dose is determined, the anti-cancer activity of SC16LD6.5 will be assessed by measuring the extent of tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a protein that appears to be expressed on the surface of most small cell lung cancers that have been assessed using an immunohistochemical assay. The drug, D6.5, is a very potent form of chemotherapy, specifically a DNA-damaging agent, that is cell cycle independent. ADC's theoretically provide more precise delivery of chemotherapy to cancer cells, possibly improving effectiveness relative to toxicities.

NCT ID: NCT01803269 Terminated - Clinical trials for Extensive Stage Small Cell Lung Cancer

Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer

Start date: January 16, 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well giving topotecan hydrochloride or cyclodextrin-based polymer-camptothecin CRLX101 works in treating patients with recurrent small cell lung cancer. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclodextrin-based polymer-camptothecin CRLX101 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether topotecan hydrochloride is more effective than cyclodextrin-based polymer-camptothecin CRLX101 in treating patients with lung cancer.

NCT ID: NCT01457469 Completed - Clinical trials for Tobacco Use Disorder

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer

Start date: January 2011
Phase: Phase 1
Study type: Interventional

This randomized clinical trial studies enhanced quitline intervention in smoking cessation for patients with non-metastatic lung cancer. Stop-smoking plans suggested by doctors may help patients with early-stage cancer quit smoking

NCT ID: NCT01325753 Withdrawn - Clinical trials for Stage IV Non-small Cell Lung Cancer

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Start date: March 2011
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the side effects of cryotherapy (cryoablation [CA]) in treating patients with lung cancer. Cryotherapy kills cancer cells by freezing them.